ClinicalTrials.gg

Program

perfluorohexyloctane

Also written as “NOV03”, “Miebo” and “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”.

Its studies are mostly in Dry Eye Syndromes, led by 2 companies.

Furthest: phase 4, since Jan 19, 202311 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies101 open or runningphase 4since Jan 19, 2023Oct 23, 2019none ahead
Novaliq10 open or runningphase 2since Nov 2, 2017Nov 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2017First study: phase 2 study in Dry Eye SyndromesNew to NovaliqNovaliq · NCT03333057 · 336 enrolled · United States
  2. Oct 23, 2019Bausch Health Companies's first studies: 2 phase 3 studies in Dry Eye SyndromesNew to Bausch Health CompaniesBausch Health Companies · NCT04140227, NCT04139798
  3. Sep 23, 2020Phase 3 study in Dry Eye SyndromesBausch Health Companies · NCT04567329 · 620 enrolled · United States
  4. Jan 19, 2023Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT05723770 · 33 enrolled · United States
  5. Mar 7, 20242 phase 4 studies in Dry Eye SyndromesBausch Health Companies · NCT06309953, NCT06346340
  6. Aug 20, 2024Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT06565650 · 216 enrolled · United States
  7. Jun 27, 2025Phase 4 study in Dry Eye SyndromesBausch Health Companies · NCT07054606 · 104 enrolled · United States
  8. Aug 6, 2025Phase 2 study in Dry Eye SyndromesBausch Health Companies · NCT07128628 · 443 enrolled · United States
  9. Aug 6, 2025Phase 3 study in Dry Eye SyndromesBausch Health Companies · NCT07111013

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07128628Dry Eye Syndromes · United States2CompletedBausch Health CompaniesMay 28, 2026443
NCT07111013Dry Eye Syndromes3WithdrawnBausch Health CompaniesApr 20270
NCT07054606Dry Eye Syndromes · United States4CompletedBausch Health CompaniesNov 3, 2025104
NCT06565650Dry Eye Syndromes · United States4Active, not recruitingBausch Health CompaniesNov 2025216
NCT06346340Dry Eye Syndromes · United States4CompletedBausch Health CompaniesFeb 24, 202597
NCT06309953Dry Eye Syndromes · United States4CompletedBausch Health CompaniesJun 17, 202499
NCT05723770Dry Eye Syndromes · United States4CompletedBausch Health CompaniesDec 23, 202333
NCT04567329Dry Eye Syndromes · United States3CompletedBausch Health CompaniesAug 30, 2021620
NCT04140227Dry Eye Syndromes · United States3CompletedBausch Health CompaniesJan 5, 2022256
NCT04139798Dry Eye Syndromes · United States3CompletedBausch Health CompaniesMar 12, 2021599
NCT03333057Dry Eye Syndromes · United States2CompletedNovaliqMay 18, 2018336

How it is read

Names in the registry

  • “NOV03”, 4 entries
  • “Miebo”, 3 entries
  • “Lifitegrast/Perfluorohexyloctane Fixed Dose Combination”, 1 entry
  • “Perfluorohexyloctane ophthalmic solution”, 1 entry
  • “Lifitegrast/perfluorohexyloctane (PFHO)”, 1 entry

Codes read as this program: NOV03.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.